JP5801197B2 - 痛みの治療に関する薬剤及び方法 - Google Patents

痛みの治療に関する薬剤及び方法 Download PDF

Info

Publication number
JP5801197B2
JP5801197B2 JP2011525298A JP2011525298A JP5801197B2 JP 5801197 B2 JP5801197 B2 JP 5801197B2 JP 2011525298 A JP2011525298 A JP 2011525298A JP 2011525298 A JP2011525298 A JP 2011525298A JP 5801197 B2 JP5801197 B2 JP 5801197B2
Authority
JP
Japan
Prior art keywords
pain
tat
peptide
nr2b9c
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011525298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501973A (ja
JP2012501973A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ピー． ベルメアース
マイケル ピー． ベルメアース
ジェー． デービッド ガーマン
ジェー． デービッド ガーマン
ピーター エス． ルー
ピーター エス． ルー
マイケル ダブリュ． サルター
マイケル ダブリュ． サルター
マイケル ティミアンスキ
マイケル ティミアンスキ
Original Assignee
ノノ インコーポレイテッド
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド, ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2012501973A publication Critical patent/JP2012501973A/ja
Publication of JP2012501973A5 publication Critical patent/JP2012501973A5/ja
Application granted granted Critical
Publication of JP5801197B2 publication Critical patent/JP5801197B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011525298A 2008-09-03 2009-09-02 痛みの治療に関する薬剤及び方法 Expired - Fee Related JP5801197B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9402608P 2008-09-03 2008-09-03
US61/094,026 2008-09-03
PCT/US2009/055786 WO2010028089A2 (en) 2008-09-03 2009-09-02 Agents and methods for treatment of pain

Publications (3)

Publication Number Publication Date
JP2012501973A JP2012501973A (ja) 2012-01-26
JP2012501973A5 JP2012501973A5 (cg-RX-API-DMAC7.html) 2012-08-30
JP5801197B2 true JP5801197B2 (ja) 2015-10-28

Family

ID=41797838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525298A Expired - Fee Related JP5801197B2 (ja) 2008-09-03 2009-09-02 痛みの治療に関する薬剤及び方法

Country Status (7)

Country Link
US (3) US8324168B2 (cg-RX-API-DMAC7.html)
EP (1) EP2334315B1 (cg-RX-API-DMAC7.html)
JP (1) JP5801197B2 (cg-RX-API-DMAC7.html)
CN (1) CN102202677A (cg-RX-API-DMAC7.html)
AU (1) AU2009288088B2 (cg-RX-API-DMAC7.html)
CA (1) CA2739416C (cg-RX-API-DMAC7.html)
WO (1) WO2010028089A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
AU2009288088B2 (en) 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
EP2621512B1 (en) * 2010-10-01 2016-04-06 NsGene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN104768568A (zh) * 2012-05-18 2015-07-08 詹森生物科技公司 虎纹捕鸟蛛毒素-iv变体及其使用方法
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
CN103012597B (zh) * 2012-12-31 2014-06-11 黑龙江大学 用于治疗骨质疏松症和止痛的OGP-CTx融合蛋白及编码该融合蛋白的核酸
KR20160064192A (ko) 2013-10-03 2016-06-07 얀센 바이오테크 인코포레이티드 프로톡신-ii 변이체 및 사용 방법
WO2015164378A1 (en) 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Analysis of compounds for pain and sensory disorders
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
US10048275B2 (en) 2015-03-13 2018-08-14 Q-State Biosciences, Inc. Cardiotoxicity screening methods
BR112017020896A2 (pt) 2015-04-02 2018-07-10 Janssen Biotech Inc variantes de protoxina-ii e métodos de uso
CN107312071B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
CN107913395B (zh) * 2016-10-10 2019-12-13 拜西欧斯（北京）生物技术有限公司 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
US11767344B2 (en) 2017-07-05 2023-09-26 Biocells (Beijing) Biotech Co., Ltd. Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar)
EA202090802A1 (ru) 2017-09-30 2020-08-05 Биоселз (Бейдзин) Биотек Ко., Лтд. Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
CN109232745B (zh) * 2018-09-18 2020-02-28 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽
CN109265557B (zh) * 2018-09-18 2019-12-24 深圳瑞健生物科技有限公司 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用
CN109265558B (zh) * 2018-09-18 2019-12-24 深圳瑞健生物科技有限公司 改进型齐考诺肽在制备药物中的应用
CN109106942B (zh) * 2018-09-18 2019-11-22 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽在制备药物中的应用
US20220110851A1 (en) * 2018-12-26 2022-04-14 Skinmed Co., Ltd. Acetylcholine receptor inhibitory peptides and uses thereof
CN111097037A (zh) * 2020-01-16 2020-05-05 刘成龙 一种psd95-pdz1/2结构域抑制剂及其应用
CN120958011A (zh) * 2023-03-31 2025-11-14 青岛普美圣医药科技有限公司 具有延长的半衰期和提高的稳定性的多肽活性分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7760905B2 (en) 1999-06-29 2010-07-20 Digimarc Corporation Wireless mobile phone with content processing
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US7858322B2 (en) * 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US20080227684A1 (en) * 2005-12-30 2008-09-18 Belmares Michael P Small Molecule Inhibitors of PDZ Interactions
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
GB0610868D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008006117A2 (en) * 2006-07-07 2008-01-10 Bioassets Development Corporation Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US20080124698A1 (en) 2006-11-28 2008-05-29 Ebensberger Jason M Virtual coatings application system with structured training and remote instructor capabilities
BRPI0720730A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat.
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
CA2693256A1 (en) * 2007-04-06 2008-10-16 Kai Pharmaceuticals, Inc. Methods of use of gamma inhibitor compounds for the attenuation of pain
US20100204100A1 (en) * 2007-04-19 2010-08-12 The Johns Hopkins Univeristy Biological agents active in central nervous system
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
AU2009288088B2 (en) 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
CA2781888C (en) * 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases

Also Published As

Publication number Publication date
US9365620B2 (en) 2016-06-14
US20150018283A1 (en) 2015-01-15
US8324168B2 (en) 2012-12-04
CA2739416A1 (en) 2010-03-11
EP2334315A2 (en) 2011-06-22
US8748387B2 (en) 2014-06-10
JP2012501973A (ja) 2012-01-26
CA2739416C (en) 2017-10-31
EP2334315B1 (en) 2023-01-18
EP2334315A4 (en) 2012-08-15
WO2010028089A2 (en) 2010-03-11
AU2009288088B2 (en) 2014-12-04
AU2009288088A1 (en) 2010-03-11
CN102202677A (zh) 2011-09-28
US20130137641A1 (en) 2013-05-30
US20100062985A1 (en) 2010-03-11
WO2010028089A3 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
CN101678068B (zh) 不抑制n型钙通道而治疗中风和其他疾病
CN101072577B (zh) ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
AU695166B2 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US9629892B2 (en) Treatment of penetrative injury to the brain
WO2010070047A1 (en) Soluble polypeptides for use in treating autoimmune and inflammatory disorders
KR20240025721A (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
Sadeghi et al. Structure–activity studies reveal the molecular basis for GABAB-receptor mediated inhibition of high voltage-activated calcium channels by α-conotoxin Vc1. 1
JP2025011136A (ja) ジルコプランによる神経疾患治療
US10800815B2 (en) Kv1.3 potassium channel antagonists
JP6073230B2 (ja) Ｎｄ２ペプチドおよび神経疾患の治療方法
US9617325B2 (en) Treatment of IgE-mediated disease
WO2015110589A1 (en) Mimetic peptides and their use in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120712

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150826

R150 Certificate of patent or registration of utility model

Ref document number: 5801197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees